PerkinElmer : Q2 2021 Earnings Presentation

2Q21 Earnings

Presentation

July 26, 2021

SAFE HARBOR

This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, plans concerning business development opportunities, acquisitions or divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward- looking statements. A detailed description of these risk factors can be found under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in the embedded hyperlinkand is available on the

"Financial Information" section of our website at www.perkinelmer.com.

2

2Q '21 FINANCIAL RESULTS

Org. Rev	41%	Adj Op	535bps	Adj EPS	81%
Margin
Growth			Growth

Revenue Mix (%) & Organic Growth Highlights

Adjusted Revenue: $1.23 billion; +51% y/y

42%

DAS

• Organic: +41%; M&A: +6%; FX: +5%
• COVID: $365 million vs. $196 million in 2Q20
• Non-COVID:+28% organic growth

Adj Op Margin: 33.5%; +535 basis points y/y

• +70 basis point adj gross margin expansion to 57.8%
• Drivers: volume leverage, mix, and productivity programs

Adj EPS: $2.83; +81% growth y/y

Adj Free Cash Flow: $267 million (84% non-GAAPconversion);

+111% y/y

APAC

25%

+DD

28%

+DD

EMEA

DX 58%

+DD

Americas

47%

+DD

+DD

Non-

Recurring

21%

+DD

79%

+DD

Recurring

Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink	3

DISCOVERY & ANALYTICAL SOLUTIONS

2Q21 Performance
Food*
	Life
•	+31% reported growth	Sciences
	• Organic: +22%; M&A: +6%; FX: +4%
	• All three regions posted at least 20%
$0.5B	organic growth	Food
2Q21 revenue
• Adj Op margins of 19.6% increased
Ind/Env	approximately 500 basis points y/y
	• Higher volume leverage &
Life Science	productivity programs
Ind/Env

• DD organic growth with Pharma/Biotech up DD and Acad/Gov't up DD
• Discovery (+DD) and Analytical (+DD) drove Pharma/Biotech performance
• DD organic growth
• Food Quality & Safety demand up DD, Cannabis activity improving
• DD Industrial & Env. organic growth
• Broad-basedmomentum across portfolio; Semiconductor demand robust, up DD

NexION ICP-MS

Cisbio Alpha Kit

QSight Triple Quad

ELN & Signals Notebook

Opera Phenix HCS

OneSource

*Food is split from Applied to illuminate the business segment. Applied in the chart above is comprised of Industrial & Environmental end-markets	4
Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink

DIAGNOSTICS

Applied

Genomics

ImmunoDx

$0.7B

2Q21 revenue

Reproductive

Health

2Q21 Performance

Reproductive

Health

• +70% reported growth
• • Organic: +59%; M&A: +6%; FX: +5%
  • Non-COVIDdiagnostics +40% organic growth

ImmunoDx

• Adj Op margins of 45.9% expanded 80 basis points y/y
• • Strong operating expense leverage

Applied

Genomics

• DD organic growth driven by clinical diagnostics franchise
• Ongoing birth rate pressures offset by improved utilization & menu expansion
• TD organic growth
• Strong DD non-COVID EuroImmun growth led by autoimmune & allergy
• DD growth y/y
• Liquid handling demand increased over 70% y/y despite difficult comparisons

GSP

GSP MM Kit

Vanadis View®*

chemagic 360

EUROIMMUN ELISA Kit

EUROLabWorkstation

*Vanadis View® is one of three systems in the Vanadis NIPT workflow: Vanadis Extract®, Vanadis Core®, and Vanadis View®	5
Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink